Applied Therapeutics, Inc. (APLT )

Currency in USD Disclaimer
$0.3 +$0.08 (36.1%)
Open 11/17/2025
$0.22
$0.4
$0.22
$10.48

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol APLT
  • Company Applied Therapeutics, Inc.
  • Price $0.3
  • Changes Percentage 36.1
  • Change 0.0788
  • Day Low $0.22
  • Day High $0.4
  • Year High $10.48
  • Year Low $0.22
  • Market Cap $42,901,212
  • Price Avg 50 EMA (D) $0.87
  • Price Avg 200 EMA (D) $0.56
  • Exchange NASDAQ
  • Volume 280,785,948
  • Average Volume 6,345,359
  • Open $0.25
  • Previous Close $0.22
  • EPS -0.1
  • PE -2.98
  • Earnings Announcement 2025-11-13 13:30:00
  • Shares Outstanding $144,012,125

Company brief: APPLIED THERAPEUTICS, INC. (APLT )

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

APLT Corporation News

Income Statement